Investigating natural compounds to target specific factors in breast cancer treatment
Elucidating the mode of action of the abietanes to develop potential therapeutic agents_supplement
This study is looking at new natural compounds that might help treat triple negative breast cancer by targeting specific proteins that are too active in cancer cells, with the goal of finding treatments that can kill cancer cells without harming healthy ones.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louisiana State Univ A&m Col Baton Rouge NIH-funded |
| Lab location | 1 site (Baton Rouge, United States) |
| Project ID | NIH-10798580 on NIH RePORTER |
What this research studies
This research focuses on developing new therapeutic agents derived from abietane natural products to target eukaryotic initiation factors (eIFs) that are overexpressed in breast cancer, particularly in triple negative breast cancer (TNBC). The approach involves testing these compounds in cellular models to assess their ability to inhibit cancer cell viability while sparing non-cancerous cells. By understanding how these compounds affect protein synthesis and signaling pathways, the research aims to provide insights into potential new treatments for patients with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who may benefit from novel therapeutic approaches.
Not a fit: Patients with non-malignant breast conditions or those with other types of breast cancer may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with triple negative breast cancer, a subtype that currently has limited targeted therapies.
How similar studies have performed: Previous research has shown promise in targeting eIFs for cancer treatment, suggesting that this approach could be a viable avenue for developing new therapies.
Where this research is happening
Baton Rouge, United States
- Louisiana State Univ A&m Col Baton Rouge — Baton Rouge, United States (Active)
Researchers
- Principal investigator: Rivas, Fatima R — Louisiana State Univ A&m Col Baton Rouge
- Study coordinator: Rivas, Fatima R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.